CJC-1295 Compounded vs Branded: A Clinical Comparison

What Is CJC-1295 and Why Does the Compounded vs Branded Question Matter?

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) derived from the first 29 amino acids of the native peptide, often called modified GRF 1-29. No FDA-approved branded product exists for this molecule in the United States as of 2025. Every vial dispensed to U.S. Patients comes from a compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

That distinction has real clinical consequences. Without an approved reference product, prescribers cannot compare compounded batches against a standardized label for potency, impurities, or sterility. The FDA's guidance on compounded drug quality under 503B outsourcing facilities sets out current good manufacturing practice (CGMP) requirements, but individual 503A pharmacies follow USP <797> sterile compounding standards instead of full CGMP.

Why No Branded Version Exists

The original CJC-1295 with DAC was developed by ConjuChem Biotechnologies in the early 2000s. Phase I/II data were published in 2006 by Teichman et al. In the Journal of Clinical Endocrinology and Metabolism, showing promising GH and IGF-1 effects [1]. ConjuChem did not advance the compound through a full Phase III program, so an NDA was never filed. The molecule subsequently entered the compounding market.

The 503A vs 503B Distinction

A 503A pharmacy fills a prescription for an identified individual patient. Quality oversight comes from state boards of pharmacy plus USP <797> [2]. A 503B outsourcing facility may produce larger batches without patient-specific prescriptions and must meet FDA CGMP standards, which include finished-product testing for identity, potency, sterility, endotoxins, and particulate matter [3]. Patients receiving CJC-1295 from a 503B facility have modestly stronger quality assurance, though neither pathway equals the scrutiny an approved NDA product receives.

CJC-1295 With DAC vs Without DAC: Two Different Drugs

The DAC (Drug Affinity Complex) modification attaches a lysine-maleimide linker to the peptide backbone that covalently binds serum albumin after injection. This single structural difference changes nearly every clinically relevant parameter.

Pharmacokinetics

CJC-1295 without DAC (mod GRF 1-29) has a plasma half-life of roughly 30 minutes, similar to endogenous GHRH [1]. It produces a sharp, pulse-like GH release that mimics physiologic secretion. CJC-1295 with DAC, by contrast, circulates bound to albumin and has a terminal half-life of 6 to 8 days in humans [1]. Teichman et al. (2006) reported that a single subcutaneous injection of 60 mcg/kg CJC-1295-DAC elevated mean 24-hour GH concentrations 2- to 3-fold above baseline for 6 days, and IGF-1 remained elevated above baseline through day 14 in higher-dose cohorts [1].

Dosing Implications

Because of the prolonged action, CJC-1295-DAC is typically administered once every 1 to 2 weeks at 1,000 to 2,000 mcg per injection. Mod GRF 1-29 (without DAC) requires far more frequent dosing, generally 100 to 300 mcg subcutaneously 3 to 5 times per week, often combined with a GHRP such as ipamorelin to amplify pulsatile GH release [4]. These dosing intervals are not arbitrary; they reflect the underlying pharmacokinetic data rather than tradition or preference.

IGF-1 Response Profile

In the Teichman trial (N=65, randomized, placebo-controlled), the highest dose cohort of CJC-1295-DAC (60 mcg/kg, single dose) produced a mean IGF-1 increase of approximately 66% above baseline at day 7 [1]. The placebo group showed no meaningful change. The without-DAC form has not been evaluated in an equivalently powered controlled trial, which means the IGF-1 data for mod GRF 1-29 at compounded doses come primarily from pharmacist extrapolation and clinical observation rather than peer-reviewed evidence.

Quality and Purity: What Compounding Pharmacies Can and Cannot Guarantee

The absence of an approved reference product means there is no FDA-established standard for CJC-1295 potency. A compounding pharmacy synthesizes or sources the bulk drug substance (BDS) from a peptide manufacturer, then tests the finished product. The depth of that testing varies.

Certificate of Analysis Requirements

A reputable 503A or 503B pharmacy should provide a certificate of analysis (COA) for each lot that includes: HPLC purity (ideally >98%), mass spectrometry confirmation of molecular weight (CJC-1295-DAC molecular formula C165H269N47O46, MW approximately 3647 Da), sterility testing per USP <71>, bacterial endotoxin testing per USP <85>, and particulate matter evaluation per USP <788> [2]. USP compounding standards define minimum sterile preparation requirements that all 503A pharmacies must meet.

Peptide Degradation Risks

CJC-1295, like all peptides, is susceptible to oxidation, deamidation, and aggregation if stored improperly. A 2020 analysis of compounded peptide products (not specific to CJC-1295 but applicable to the class) found that a subset of samples failed potency specifications when stored at non-refrigerated temperatures for more than 48 hours [5]. Patients should receive vials in cold-chain shipping with instructions to refrigerate at 2 to 8 degrees Celsius and use within 28 days of reconstitution, consistent with USP <797> beyond-use dating for Category 2 sterile preparations [2].

No Branded Comparator Exists

Because there is no FDA-approved branded CJC-1295, the phrase "compounded vs branded" is somewhat of a misnomer. The real comparison is between different compounding pharmacies or between CJC-1295 and FDA-approved growth hormone products such as somatropin (Genotropin, Norditropin, Humatrope, Saizen) [6]. Somatropin undergoes full NDA review including bioequivalence, manufacturing consistency, and post-market pharmacovigilance that compounded CJC-1295 simply does not.

Clinical Evidence Base: What the Trials Actually Show

The evidence base for CJC-1295 in humans is thin by modern standards.

Teichman et al. 2006 (JCEM)

This Phase I/II randomized, double-blind, placebo-controlled dose-escalation study enrolled 65 healthy adults aged 21 to 61 years [1]. Participants received single subcutaneous doses of CJC-1295-DAC at 30, 60, or 120 mcg/kg, or multiple doses. Key results: mean GH area-under-the-curve increased 2- to 3-fold in the 60 and 120 mcg/kg cohorts; IGF-1 elevation persisted for up to 14 days; the compound was well tolerated, with flushing (30%), headache (18%), and injection-site reactions (10%) as the most common adverse events [1]. No subjects developed antibodies to GH or GHRH over the study period. This remains the only peer-reviewed, placebo-controlled human trial for this molecule.

Absence of Phase III Data

No Phase III trial for CJC-1295 has been completed or published. The FDA requires Phase III evidence for NDA approval of a new molecular entity [7]. Prescribers should be explicit with patients that they are using a peptide supported by a single Phase I/II study. That is a meaningful gap compared with somatropin, which has decades of safety data across multiple indications including adult GH deficiency [8].

IGF-1 as a Surrogate Endpoint

IGF-1 elevation is the primary biomarker used to monitor CJC-1295 therapy, but it is a surrogate, not a clinical outcome. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states that IGF-1 targets should be interpreted in the context of age- and sex-matched reference ranges, typically aiming for the upper half of normal (0 to +2 SDS) [9]. Using IGF-1 as the sole treatment target without validating patient-reported outcomes or body composition changes limits the interpretive value of any positive lab result.

Regulatory Status and Prescribing Considerations

The FDA considers CJC-1295 a bulk drug substance. Its eligibility for use in compounding under Section 503A and 503B depends on whether it appears on an FDA-designated list of approved or nominated bulk substances.

FDA Bulk Drug Substance Lists

Under Section 503A, pharmacists may compound using bulk drug substances that are either: (a) a component of an FDA-approved drug; (b) the subject of a USP or NF monograph; or (c) on the 503A bulks list [10]. CJC-1295 does not have a USP monograph and is not a component of an approved drug, so its 503A eligibility depends entirely on its status on the nominated-but-not-yet-determined list. The FDA has not formally placed CJC-1295 on either the Category 1 (may be used) or Category 2 (may not be used) list for 503A as of the time of this publication, meaning its legal status for compounding remains in a regulatory gray zone [10]. Prescribers and pharmacies should check the current FDA 503A bulks list before prescribing or dispensing.

Prescribing Requirements

CJC-1295 requires a valid prescription from a licensed prescriber. Off-label use of GHRH analogs for wellness, anti-aging, or body composition is not supported by any FDA-approved indication. The World Anti-Doping Agency (WADA) prohibits GHRH analogs including CJC-1295 on its Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) [11]. Athletes subject to drug testing should be counseled accordingly.

Monitoring Parameters

Clinicians prescribing compounded CJC-1295 should monitor: fasting IGF-1 at baseline and 4 to 6 weeks after initiating therapy; fasting glucose and HbA1c, because sustained GH elevation reduces insulin sensitivity [9]; blood pressure and fluid retention symptoms; and any signs of pituitary tumor growth in patients with a history of pituitary disease. The Endocrine Society guideline on adult GH deficiency recommends against GH therapy in patients with active malignancy [9], a caution that reasonably extends to GH secretagogues.

How Compounded CJC-1295 Is Typically Formulated and Dispensed

Compounded CJC-1295 arrives as a lyophilized (freeze-dried) powder in a sterile multi-dose vial, typically 2 mg or 5 mg per vial. Reconstitution uses bacteriostatic water for injection (0.9% benzyl alcohol) at a volume calculated to achieve the desired concentration, commonly 200 mcg per 0.1 mL for the without-DAC variant.

Common Combination Protocols

Many compounding prescriptions combine CJC-1295 without DAC with ipamorelin, a selective GHRP-2 analog with a low side-effect profile. The rationale is mechanistic: CJC-1295 acts on the GHRH receptor to prime somatotroph cells, while ipamorelin acts on the ghrelin receptor (GHSR-1a) to trigger GH pulse release [4]. Animal studies and pharmacological modeling suggest the combination produces synergistic GH output compared with either agent alone, though no controlled human trial has directly tested the combination at clinical doses [4]. The typical combined compounded formulation provides 150 to 300 mcg of each peptide per injection.

Beyond-Use Dating

Under revised USP <797> (effective November 2023), Category 2 sterile preparations may have a maximum beyond-use date of 45 days refrigerated [2]. Most compounding pharmacies assign 28 to 45 days for reconstituted CJC-1295 with bacteriostatic water. Patients using multi-dose vials should discard any remaining solution after the labeled beyond-use date regardless of apparent clarity.

Side Effects, Contraindications, and Drug Interactions

Adverse Effects Documented in Teichman et al.

The Teichman 2006 trial documented flushing in 30% of subjects, headache in 18%, and injection-site erythema or pain in approximately 10% [1]. These events were predominantly mild to moderate and self-limited. No serious adverse events were attributed to CJC-1295-DAC at doses up to 120 mcg/kg. The trial duration was short (28 days follow-up), so long-term safety data do not exist from controlled study.

GH-Class Adverse Effects

Because CJC-1295 raises endogenous GH and IGF-1, the adverse effects associated with GH excess apply. These include fluid retention and edema, arthralgia, carpal tunnel syndrome, and insulin resistance [8]. Acromegaly has not been reported in the clinical literature with CJC-1295 at therapeutic doses, but sustained supraphysiologic IGF-1 concentrations would theoretically carry similar risk. The FDA's labeling for somatropin products warns of increased risk of progression of preexisting neoplasms [6].

Drug Interactions

CJC-1295 may blunt the GH response to any agent that raises somatostatin tone, including glucocorticoids, which suppress the GHRH-GH axis at multiple levels [9]. Concurrent use of insulin or insulin sensitizers may partially counteract the insulin resistance induced by elevated GH. No formal pharmacokinetic drug interaction studies have been conducted for CJC-1295.

Absolute Contraindications

Active malignancy, known pituitary tumor, proliferative or severe nonproliferative diabetic retinopathy, and pregnancy are contraindications drawn by analogy from approved somatropin prescribing information [6]. Patients with type 2 diabetes or impaired fasting glucose require careful glucose monitoring, with HbA1c checked no less than every 3 months during active therapy.

Comparing Compounded CJC-1295 to FDA-Approved Somatropin

The most clinically meaningful comparison is not compounded CJC-1295-DAC vs a hypothetical branded CJC-1295, but compounded CJC-1295 vs approved somatropin products for adult GH deficiency.

Somatropin (recombinant human GH, 191 amino acids) is FDA-approved for adult GH deficiency, short bowel syndrome, HIV-associated wasting, and other indications [6]. It is administered as a daily subcutaneous injection, typically 0.15 to 0.30 mg/day with titration based on IGF-1 and tolerability. Somatropin has 40-plus years of post-marketing safety data, standardized lot testing, FDA-inspected manufacturing, and pharmacovigilance programs. CJC-1295 has one Phase I/II trial, no post-marketing program, and no standard lot testing requirement [1].

The clinical trade-off that CJC-1295 offers is oral appetite sparing (since it stimulates endogenous pulsatile GH rather than replacing it) and the preservation of hypothalamic-pituitary feedback, which may theoretically reduce the risk of pituitary axis suppression. These theoretical advantages have not been tested in head-to-head trials against somatropin.

For patients with confirmed GH deficiency by stimulation testing (peak GH <5 mcg/L on two stimulation tests, per Endocrine Society criteria [9]), somatropin is the evidence-based, FDA-approved choice. CJC-1295 is not an FDA-approved substitute for somatropin in diagnosed GH deficiency.

What Prescribers and Patients Should Ask Before Starting Compounded CJC-1295

Patients and clinicians should ask eight specific questions before proceeding:

1. Is the pharmacy 503A or 503B, and can it provide a current COA with HPLC purity, mass spec confirmation, sterility, and endotoxin results?
2. Has CJC-1295 been checked against the current FDA 503A or 503B bulks list for legal dispensing status [10]?
3. Is the prescribing indication medically supported (e.g., documented suboptimal IGF-1 for age, or wellness/body-composition optimization without GH deficiency diagnosis)?
4. Has baseline IGF-1, fasting glucose, HbA1c, and a thorough history for malignancy been obtained?
5. Is the patient subject to WADA drug testing, given the explicit prohibition on GHRH analogs [11]?
6. What is the pharmacy's cold-chain shipping protocol and stated beyond-use date?
7. Is the patient on glucocorticoids, which may significantly attenuate the GH response [9]?
8. What is the follow-up plan for IGF-1 monitoring at 4 to 6 weeks?

Obtaining a signed informed consent that explicitly documents the off-label, compounded, and limited-evidence nature of CJC-1295 therapy protects both prescriber and patient.